Skip to main content
OpenTrials
Completed

NCT Number: NCT04798209

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

A study to examine the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-777991 in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

QPS Netherlands B.V.

Groningen, 9713 GZ, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

General Inclusion Criteria:

  • Signed informed consent in a language understandable to the subject prior to any study-mandated procedure.
  • Healthy male (Part A and B) and female subjects (Part B) aged between 18 and 55 years (inclusive) at Screening.
  • Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.
  • Male subjects with a partner who might become pregnant must either be vasectomized or agree to practice adequate contraception from admission to the study site until 3 months after dosing, or the partner must consistently and correctly use a highly effective method of contraception.

Inclusion criteria

for Part B:

  • Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use a highly effective method of contraception with a failure rate of less than 1% per year, be sexually inactive, or have a vasectomized partner.
  • Women of non-childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1.

General Exclusion Criteria:

  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment.

Exclusion criteria

for the absorption,distribution, metabolism and excretion (ADME) evaluation:

  • Radiation exposure, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 milli sievert (mSv) in the last 12 months or 10 mSv in the last 5 years. Occupationally exposed workers, as defined in the relevant Ionising Radiation Regulations, must not participate in the study.
  • Participation in any study involving administration of any Carbon-14 (14C) radiolabeled compound within the 12 months prior to Screening.

Exclusion criteria

for Part B:

  • Pregnant or lactating women.

Treatment and study plan

ACT-777991 (SAD)

Drug

ACT-777991 administered as hard capsules for oral use.

ACT-777991 (MAD)

Drug

ACT-777991 administered as hard capsules for oral use, once daily.

Placebo (SAD)

Drug

ACT-777991 matching placebo administered as hard capsules for oral use.

Placebo (MAD)

Drug

Matching placebo administered as hard capsules for oral use, once daily.

14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)

Drug

Single dose of 14C-ACT-777991 microtracer, administered intravenously.

Microtracer matching placebo (SAD - Absolute Bioavailability)

Drug

Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.

14C-ACT-777991 microtracer (MAD - ADME)

Drug

Single dose of 14C-ACT-777991 microtracer, oral solution..

Microtracer matching placebo (MAD - ADME)

Drug

Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.

Primary outcomes

  1. Incidence of treatment-emergent adverse events.

    Time frame: From first dose on Day 1 to Day 4 after the last dose was administered

Secondary outcomes

  1. All cohorts: Area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  2. All cohorts: Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  3. All cohorts: Maximum plasma concentration (Cmax) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  4. All cohorts: Time to reach Cmax (tmax) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  5. All cohorts: Terminal half-life (t1/2) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  6. Part A (SAD): Absolute bioavailability of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  7. Part B (MAD): Excretion of radioactivity in urine and feces

    Time frame: Samples will be collected at predefined time points from Day 1 to Day X+3 (where Day X = day of last study treatment administration)

  8. Part B (MAD): AUC during a dosing interval (AUCτ) following the first and the last dose of ACT-777991.

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  9. Part A (SAD): Food effect evaluation only: AUC0-inf of ACT-777991 under fed conditions

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.

  10. Part A (SAD): Food effect evaluation only: Cmax of ACT-777991 under fed conditions

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.

  11. Part A (SAD): Food effect evaluation only: tmax of ACT-777991 under fed conditions

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.

  12. Part A (SAD): Food effect evaluation only: t1/2 of ACT 777991 under fed conditions

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.

Sponsors and collaborators

Lead sponsor

Idorsia Pharmaceuticals Ltd.

Industry

Registry information

Official study title

A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Mar 15, 2021
Registry last updated
Jun 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.